Siemens Healthineers AG (BIT:1SHL)
Italy · Delayed Price · Currency is EUR | Market Cap | 39.14B -27.2% |
| Revenue (ttm) | 23.07B -0.3% |
| Net Income | 2.10B +0.3% |
| EPS | 1.86 +0.2% |
| Shares Out | n/a |
| PE Ratio | 18.68 |
| Forward PE | 14.66 |
| Dividend | 1.00 (2.86%) |
| Ex-Dividend Date | Feb 6, 2026 |
| Volume | 1,160 |
| Open | 34.92 |
| Previous Close | 35.94 |
| Day's Range | 34.91 - 34.92 |
| 52-Week Range | 32.99 - 52.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About Siemens Healthineers AG
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers in Germany, the United States, rest of Europe, CIS, Africa, the Middle East, the Americas, the Asia Pacific, Japan, and China. It operates in four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment offers magnetic resonance imaging, computed tomography, X-ray, molecular imaging, and ultrasound systems; and software solutions to support the readin... [Read more]
Financial Performance
In fiscal year 2025, Siemens Healthineers AG's revenue was 23.38 billion, an increase of 4.53% compared to the previous year's 22.36 billion. Earnings were 2.14 billion, an increase of 10.40%.
Financial StatementsNews
EQS-CMS: Siemens Healthineers AG: Release of a capital market information
EQS Post-admission Duties announcement: Siemens Healthineers AG / Disclosure pursuant to Art. 5 para. 1 lit. a) of the Regulation (EU) No. 596/2014, as last amended by Regulation (EU) No. 2024/2809 (M...
AiM Medical Robotics Announces Collaboration Agreement with Siemens Healthineers to Advance MRI-Guided Robotic Neurosurgery
Worcester, MA, May 26, 2026 (GLOBE NEWSWIRE) -- AiM Medical Robotics, a leading developer of advanced robotic systems for MRI-guided neurosurgery, today announced a collaboration agreement with Siemen...
Siemens Healthineers price target lowered to EUR 55.80 at JPMorgan
JPMorgan lowered the firm’s price target on Siemens Healthineers (SMMNY) to EUR 55.80 from EUR 61.30 and keeps an Overweight rating on the shares.
Siemens Healthineers AG (SEMHF) Adjusts Forecast Amid Q2 Revenue Decline
Siemens Healthineers AG (SEMHF) Adjusts Forecast Amid Q2 Revenue Decline
Siemens Healthineers AG Earnings Call Transcript: Q2 2026
Imaging and precision therapy segments delivered strong growth and margin expansion in Q2 FY2026, offsetting significant FX and tariff headwinds, while Diagnostics faced revenue and margin declines due to China market challenges. FY2026 guidance was revised lower, but midterm double-digit EPS growth ambition remains intact.
Siemens Healthineers AG Slides: Q2 2026
Siemens Healthineers AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 7, 2026.
Siemens Healthineers AG Earnings release: Q2 2026
Siemens Healthineers AG released its Q2 2026 earnings on May 7, 2026, summarizing the period's financial results.
Siemens Healthineers AG Quarterly report: Q2 2026
Siemens Healthineers AG has published its Q2 2026 quarterly earnings report on May 7, 2026.
Siemens Healthineers AG Profit Declines In Q2
BRUSSELS (dpa-AFX) - Siemens Healthineers AG (SMMNY.PK) announced earnings for second quarter that Drops, from last yearThe company's earnings totaled EUR506 million, or EUR0.45 per share. This co...
Siemens Healthineers cuts 2026 outlook
Siemens Healthineers on Thursday cut its full year outlook to forecast revenue growth of between 4.5% and 5.0% for the 2026 financial year due to weakness in China's diagnostics market and high...
CDC HoST-TT Certification for Siemens Healthineers Total Testosterone Test Expands Patient Access to Gold Standard Equivalent Results
Tarrytown, NY, USA, May 04, 2026 (GLOBE NEWSWIRE) -- Siemens Healthineers announced its Atellica IM Testosterone II (TSTII) assay has achieved certification through the Centers for Disease Control and...
Siemens Healthineers price target lowered to EUR 53 from EUR 59 at Citi
Citi lowered the firm’s price target on Siemens Healthineers (SMMNY) to EUR 53 from EUR 59 and keeps a Buy rating on the shares.
Siemens plans shareholder vote on Siemens Healthineers spin-off in February 2027
Siemens said on Friday it planned a shareholder vote on a direct spin-off of Siemens Healthineers shares at its next shareholder meeting in February 2027.
Siemens Healthineers price target lowered to EUR 41 from EUR 44 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on Siemens Healthineers (SMMNY) to EUR 41 from EUR 44 and keeps an Equal Weight rating on the shares. Published…
Siemens Healthineers price target lowered to EUR 42 from EUR 46 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Siemens Healthineers (SMMNY) to EUR 42 from EUR 46 and keeps a Hold rating on the shares.
Siemens Healthineers AG Transcript: Pre-close call
Q2 revenue growth is expected below the 5%-6% outlook, with significant FX and tariff headwinds impacting margins and EBIT. Diagnostics faces pronounced declines in China, while hedging and pricing strategies aim to offset cost inflation risks.
Imaginostics Receives Siemens Healthineers Letter of Support as Companies Advance Quantitative MRI Dialogue
ORLANDO, Fla.--(BUSINESS WIRE)-- #Alzheimers--Imaginostics, Inc. today announced that it has received a Letter of Support from Siemens Healthineers in connection with ongoing exploratory discussions r...
Siemens Healthineers launches brain health research portfolio
Siemens Healthineers (SMMNY) announced its offerings for brain health research are expanding, with the brain-derived, fully automated Atellica IM Phosphorylated tau 217 and Atellica IM Brain Derived T...
Siemens Healthineers Launches Brain Health Research Portfolio with First Biomarker Assays Now Available
Brain-derived, fully automated Atellica IM Phosphorylated tau 217 (pTau217) and Atellica IM Brain Derived Tau (BDTau) assays now available for research use Brain-derived, fully automated Atellica IM P...
Dentsply Sirona, Siemens Healthineers share findings from trial of MRI system
Dentsply Sirona (XRAY) and Siemens Healthineers (SMMNY) share key findings from the clinical trial for validation of their dental-dedicated MRI system. In addition to confirming its significant potent...
Ki Reply and Data Reply Lay the Strategic Foundation for AI Innovation at Siemens Healthineers with “Cerebra”
TURIN, Italy--(BUSINESS WIRE)--Ki Reply and Data Reply, the Reply Group companies specialised respectively in AI-powered software development and data-driven solutions, have partnered with the “CRM Ex...
Siemens Healthineers AG Transcript: Status update
Imaging and Precision Therapy delivered strong growth and margins, offsetting Diagnostics' decline due to China market headwinds. H2 is expected to improve with cost reductions, core lab momentum, and new product launches, while spin-off preparations advance.
Siemens Healthineers price target lowered to EUR 59 from EUR 60 at Citi
Citi lowered the firm’s price target on Siemens Healthineers (SMMNY) to EUR 59 from EUR 60 and keeps a Buy rating on the shares.
Siemens Healthineers Core Businesses Offset Currency, Tariff Challenges
Revenue grew on a comparable basis as results in its imaging and precision therapy business units offset currency and tariff headwinds.
Siemens Healthineers AG Earnings Call Transcript: Q1 2026
Imaging and precision therapy delivered strong growth and margin expansion, offsetting diagnostics' revenue decline driven by structural changes in China. Fiscal 2026 outlook is confirmed, with continued tariff and FX headwinds, and diagnostics expected to face further challenges in Q2.